Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the ...

The Food and Drug Administration (FDA) has approved Abrysvo ® (respiratory syncytial virus [RSV] vaccine) for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by ...

Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

The US Food and Drug Administration (FDA) has expanded the indication for Pfizer’s respiratory syncytial virus (RSV) vaccine ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

The FDA approved Pfizer's Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) ...